Beneficial Microbes: The pharmacy in the gut

被引:72
作者
Linares, Daniel M. [1 ,2 ]
Ross, Paul [2 ,3 ]
Stanton, Catherine [1 ,2 ]
机构
[1] TEAGASC, Food Res Ctr, Food Biosci Dept, Moorepk, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, Microbiome Inst, APC, Cork, Ireland
[3] Natl Univ Ireland Univ Coll Cork, Biosci Inst, Cork, Ireland
基金
爱尔兰科学基金会;
关键词
gut bacteria; health; microbiota; microbiome; probiotic; HUMAN HEALTH; PROBIOTICS; HOST; PREBIOTICS; PSYCHOBIOTICS; BACTERIA;
D O I
10.1080/21655979.2015.1126015
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The scientific evidence supporting the gut microbiome in relation to health maintenance and links with various disease states afflicting humans, from metabolic to mental health, has grown dramatically in the last few years. Strategies addressing the positive modulation of microbiome functionality associated with these disorders offer huge potential to the food and pharmaceutical industries to innovate and provide therapeutic solutions to many of the health issues affecting modern society. Such strategies may involve the use of probiotics and prebiotics as nutritional adjunct therapies. Probiotics are generally recognized to be a good form of therapy to keep harmful, intestinal microorganisms in check, aid digestion and nutrient absorption, and contribute to immune function. Probiotics are reported to improve microbial balance in the intestinal tract and promote the return to a baseline microbial community following a perturbing event (dysbiosis) such as antibiotic therapy. Prebiotics are selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microflora, which confers benefits upon host well-being and health.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 66 条
[31]   Assessing the Human Gut Microbiota in Metabolic Diseases [J].
Karlsson, Fredrik ;
Tremaroli, Valentina ;
Nielsen, Jens ;
Backhed, Fredrik .
DIABETES, 2013, 62 (10) :3341-3349
[32]   A Clinician's Primer on the Role of the Microbiome in Human Health and Disease [J].
Khanna, Sahil ;
Tosh, Pritish K. .
MAYO CLINIC PROCEEDINGS, 2014, 89 (01) :107-114
[33]   Succession of microbial consortia in the developing infant gut microbiome [J].
Koenig, Jeremy E. ;
Spor, Ayme ;
Scalfone, Nicholas ;
Fricker, Ashwana D. ;
Stombaugh, Jesse ;
Knight, Rob ;
Angenent, Largus T. ;
Ley, Ruth E. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 :4578-4585
[34]   Novel probiotics and prebiotics: road to the market [J].
Kumar, Himanshu ;
Salminen, Seppo ;
Verhagen, Hans ;
Rowland, Ian ;
Heimbach, Jim ;
Banares, Silvia ;
Young, Tony ;
Nomoto, Koji ;
Lalonde, Melanie .
CURRENT OPINION IN BIOTECHNOLOGY, 2015, 32 :99-103
[35]  
Mandal RS, 2015, GENOMICS PROTEOMICS, VS1672-0229, P00054
[36]   Comparison of the Immunomodulatory Properties of Three Probiotic Strains of Lactobacilli Using Complex Culture Systems: Prediction for In Vivo Efficacy [J].
Mileti, Erika ;
Matteoli, Gianluca ;
Iliev, Iliyan D. ;
Rescigno, Maria .
PLOS ONE, 2009, 4 (09)
[37]   The gut flora as a forgotten organ [J].
O'Hara, Ann M. ;
Shanahan, Fergus .
EMBO REPORTS, 2006, 7 (07) :688-693
[38]   Medicines from microbiota [J].
Olle, Bernat .
NATURE BIOTECHNOLOGY, 2013, 31 (04) :309-315
[39]  
Otles S., 2013, PROBIOTICS PREBIOTIC
[40]   Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study [J].
Ouwehand, Arthur C. ;
Cai DongLian ;
Xu Weijian ;
Stewart, Morgan ;
Ni, Jiayi ;
Stewart, Tad ;
Miller, Larry E. .
VACCINE, 2014, 32 (04) :458-463